General Information of Drug (ID: DMTQ2K0)

Drug Name
SelG1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Vaso-occlusive crisis BE2Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMTQ2K0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting P-selectin (SELP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizanlizumab DMAHOVJ Vaso-occlusive crisis BE2Y Approved [3]
GMI-1070 DMJ432G Asthma CA23 Phase 3 [4]
Inclacumab DMXV94M Sickle-cell disorder 3A51 Phase 3 [5]
CY-1503 DML906E Hypertension BA00-BA04 Phase 2/3 [6]
BAICALEIN DM4C7E6 Influenza virus infection 1E30-1E32 Phase 2 [7]
RPSGL-Ig DM0BFJ5 Delayed graft function 4B24.0 Phase 2 [8]
PSI-697 DM75FWO Atherosclerosis BD40 Phase 1 [9]
CDP-850 DMWHQM3 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [10]
CY-1787 DMWY2NT Allergy 4A80-4A85 Discontinued in Phase 1 [11]
PURPUROGALLIN DM63O4F N. A. N. A. Terminated [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P-selectin (SELP) TTE5VG0 LYAM3_HUMAN Not Available [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
3 Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
4 Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
5 Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
6 Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
7 Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
8 rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
9 Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
10 WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
11 Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.